Exercise in a Pill Is Now in Human Trials - Summary - MDSpire

Exercise in a Pill Is Now in Human Trials

Atrogi's ATR-258 just dosed its first subjects — and the muscle data it's hunting could reframe how we treat weight loss.

  • By

  • Kerri Miller

  • March 18, 2026

  • 2 min

Share

Objective:

To evaluate the effects of ATR-258, a compound designed to replicate the metabolic benefits of exercise, in human subjects.

Key Findings:
  • Safety and tolerability were established in a previous Phase 1 trial with 69 subjects.
  • The current trial aims to gather data on muscle physiology, including biopsies and functional measures.
Interpretation:

ATR-258 targets muscle-sparing weight loss, addressing a gap left by GLP-1 treatments focused primarily on obesity.

Limitations:
  • The study is limited to overweight men and has a narrow 8-week duration.
  • Generalizability and long-term metabolic outcomes are yet to be determined.
Conclusion:

ATR-258 could be significant in addressing muscle loss during weight loss, with results expected later this year.

Original Source(s)

Exercise in a Pill Is Now in Human Trials

  • by Kerri Miller

  • March 18, 2026

Related Content

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Digital Patient Decision Aid for Antiobesity Medications: Mixed Methods Study of Human-Centered Design and Usability Evaluation

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.